Correction
Accepted on 01 Nov 2024
Corrigendum: The Value of Second-line Anti-HER2 Therapy in Metastatic HER-2 Positive Patients: A Cost-effectiveness Analysis in China
in Drugs Outcomes Research and Policies
Correction
Accepted on 01 Nov 2024
in Drugs Outcomes Research and Policies
Original Research
Accepted on 01 Nov 2024
in Pharmacogenetics and Pharmacogenomics
Original Research
Accepted on 01 Nov 2024
in Brain-Computer Interfaces
Review
Accepted on 01 Nov 2024
in Clinical Nutrition
Original Research
Accepted on 01 Nov 2024
in Inflammation
Original Research
Accepted on 01 Nov 2024
in Veterinary and Zoonotic Infection
Systematic Review
Accepted on 01 Nov 2024
in Ethnopharmacology
Original Research
Accepted on 01 Nov 2024
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 01 Nov 2024
in Ethnopharmacology
Original Research
Accepted on 01 Nov 2024
in Reproduction
Original Research
Accepted on 01 Nov 2024
in Pediatric Hematology and Hematological Malignancies
Review
Accepted on 01 Nov 2024
in Diabetes: Molecular Mechanisms
Original Research
Accepted on 01 Nov 2024
in Diabetes: Molecular Mechanisms
Original Research
Accepted on 01 Nov 2024
in Dynamical Systems
Original Research
Accepted on 01 Nov 2024
in Gastrointestinal and Hepatic Pharmacology
Original Research
Accepted on 01 Nov 2024
in Aging and Public Health